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Amalgamation of Nucleosides and Amino Acids in Antibiotic Biosynthesis 
 
 
 
The rapid increase in antibiotic resistance demands the identification of novel 
antibiotics with novel targets.  One potential antibacterial target is the 
biosynthesis of peptidoglycan cell wall, which is both ubiquitous and necessary 
for bacterial survival. Both the caprazamycin-related compounds A-90289 and 
muraminomicin, as well as the capuramycin-related compounds A-503083 and 
A-102395 are potent inhibitors of the translocase I enzyme, one of the key 
enzymes required for cell wall biosynthesis.  The caprazamycin-related 
compounds contain a core nonproteinogen β-hydroxy-α-amino acid referred to as 
5’-C-glycyluridine (GlyU).  Residing within the biosynthetic gene clusters of the 
aforementioned compounds is a shared open reading frame which encodes a 
putative serine hydroxymethyltransferase (SHMT).  The revelation of this shared 
open reading frame resulted in the proposal that this putative SHMT catalyzes  
an aldol-type condensation reaction utilizing glycine and uridine-5’-aldehyde, 
resulting in the GlyU core.  The enzyme LipK involved in A-90289 biosynthesis 
was used as a model to functionally assign this putative SHMT to reveal its 
functions as an L-threonine: uridine-5’-aldehyde transaldolases.  Biochemical 
analysis indicates enzymatic activity is dependent upon pyridoxal-5’-phosphate, 
is non-reactive with alternative amino acids, and produces acetaldehyde as a co-
product.  Structural characterization of the enzymatic product is consistent with 
(5’S,6’S)-GlyU indicating that this enzyme orchestrates a C-C bond breaking and 
formation resulting in two new stereocenters to make a new L-α-amino acid.  The 
same activity was demonstrated for the LipK homologues involved in the 
biosynthesis of muraminomicin, A-503083, and A-102395.  This L-threonine: 
uridine-5’-aldehyde transaldolase was used with alternative aldehyde substrates 
to prepare unusual L-α-amino acids, suggesting the potential for exploiting this 
enzyme to make new compounds.  
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Chapter One 
INTRODUCTION 
 
1.1 Searching for new antibiotics 
The drastic increase in antibacterial resistance requires priority be given to the 
formation and discovery of novel antibacterial compounds.  The limited shelf life 
of antibiotics is due in part to the natural or acquired resistance mechanism of the 
organism, which has been correlated to the quantity of antibiotic used, the 
frequency of use, the size of the population it’s prescribed for, the resistance 
mechanisms for the drug already present in the organism, the quantity of 
mutations required for resistance in the organism, and the fitness of the resistant 
organism.  Currently, an innovation gap exists in finding novel antibacterial 
structures that deviate from the main classes of antibiotics; the β-lactams, the 
macrolides, sulfonamides, and the fluoroquinolones (Fig. 1.1), the majority of 
which were discovered more than 60 years ago (1).  Therefore, the search for 
novel antibacterial compounds continues. 
 
 
Figure 1.1  Structural examples of the main classes of antibiotics. 
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Natural products have been one of the leading sources of unprecedented 
bioactive compounds.  Over the last 25 years, more than 60% of small-molecule 
compounds introduced as novel drugs were derived from natural products (2).  
However, as of late, pharmaceutical companies have focused on combinatorial 
chemistry, high-throughput screening of synthetic chemical libraries, and 
computer assisted design for novel drug compound development (3).  While 
methods of identifying novel drug compounds vary over time, the consistency of 
natural products to unearth elaborate, novel compounds is still unequaled.   
Displaying complex scaffolds with richly deployed functional groups, natural 
products utilize enzymatic pathways which enable structural diversity that cannot 
be synthesized and is essential in drug development (4).  One potential strategy 
to harness the unique capabilities of these unprecedented structures and 
optimize current drug compounds, is using a biosynthetic approach for 
production and discovery of these complex compounds.  
 
1.1.1 Current antibacterial targets 
Multiple sites in bacterial replication have proven effective targets for bacterial 
growth inhibition.  Protein biosynthesis, DNA and RNA replication, thymine 
biosynthesis, cell surface decoration, isoprenoid biosynthesis, and peptidoglycan 
cell wall formation have all proven effective antibacterial targets.  Protein 
biosynthesis targeting the bacterial ribosome within the organism is one primary 
target for antibiotics.  The bacterial ribosome consists of two subunits (30S and 
50S) of rRNA and protein.  Antibiotics such as macrolides and oxazolidones bind 
	  
3 
to the 50S unit while aminoglycosides and tetracyclines bind to the 30S unit 
inhibiting protein biosysnthesis (5-7).  These inhibitors thus derail essential 
biosynthesis of proteins resulting in cell death. 
 
DNA and RNA replication, as well as thymine biosynthesis are two more classical 
antibacterial targets.  The antibiotics rifampin, ciprofloxacin, and the novobiocins 
successfully inhibit DNA and RNA formation during bacterial growth and 
therefore prevent antibacterial replication.  Rifampin functions by binding to RNA 
polymerase and therefore inhibiting the polymerase from attaching to the DNA for 
transcription. Ciprofloxacin and novobiocins repress the introduction of supercoils 
in DNA by binding to DNA gyrase.  By inhibiting DNA and RNA formation, the 
ability of the organism to survive is greatly reduced (6, 8).  Thymine, generated 
by folate metabolism and utilized in DNA formation, is another successful target 
for antibitiotics such as sulfamethoxazole and trimethoprim.   By depleting 
dihydropteroate, sulfamethoxazole inhibits dihydropteroate synthase by reducing 
the amount of dihydrofolate and thus folate.  Trimethoprim, another antibacterial 
compound successful in inhibiting bacterial replication, inhibits the formation of 
tetrahydrofolate.  By depleting dihdrofolate reductase, the compound 
trimethoprim successfully prohibits the formation of tetrahdyrofolate from 
dihydrofolate and therefore halts folate synthesis (9, 10).   
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Two more potential antibacterial targets are cell surface decoration and 
isoprenoid biosynthesis.  Sortases, present in gram-positive bacteria, are 
enzymes which cleave cell surface proteins.  These enzymes are anchored into 
the membrane by membrane spanning sequences containing an amino terminal 
and they covalently attach to the peptidoglycan cell wall by an amino terminal 
cleavage fragment of the surface protein (11).  Another unique target not present 
in higher organisms is the non-classical (non-mevalonate) pathway of isoprenoid 
biosynthesis.  Isotopic labeling studies have shown a divergence in the formation 
of isoprenoid units between most human pathogens and vertebrates.  
Vertebrates utilize the mevalonate pathway while most human pathogens 
incorporate isoprenoid units by means of the non-mevalonate pathway.  This 
alternative pathway utilizes enzymes such as 1-deoxy-D-xylulose 5-phosphate 
reductoisomerase and 1-hydroxy-2-methyl-2-(E)-butenyl D-erythritol 2,4-
cyclodiphosphate synthase which would be ideal targets for antibacterial 
compounds due to the lack of mammalian homologs (12, 13).  
 
Finally, the peptidoglycan cell wall is a prime target due to its multiple inhibition 
sites, its presence in both gram-positive and gram-negative bacteria, and its 
necessity for the survival of nearly all bacteria.   Peptidoglycan cell wall 
biosynthesis requires multiple enzymes, many of which are ideal targets for 
antibacterial inhibition.  Peptidoglycan contains N-acetylglucosamine (glcNac) 
and N-acetyl-muramic acid (MurNAc), two hexoses forming the backbone of a 
cross-linked polymer.  Lipids I and II are formed when the peptidoglycan units are 
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transferred to a carrier lipid which transports the precursors across the cellular 
membrane.  One of the key enzymatic activities is that of transporting molecules 
aided by the translocase enzymes (14). 
 
1.1.2  Formation of the Peptidoglycan cell wall 
The biosynthesis of peptidoglycan cell wall has proven a viable target for 
antibacterial compounds.  Drugs such as fosfomycin inhibiting MurA, ramoplanin 
inhibiting MurG, vancomycin inhibiting transglycolastion, and the β-lactams which 
inhibit the transpeptidation step have all been clinically used as antibiotics (15-
18).  The peptidoglycan cell wall is assembled by a series of enzymatic reactions 
within the cytoplasm as well as the periplasm that are depicted in Figure 1.2.  
The initial steps in the biosynthetic pathway are composed of stepwise additions 
of L-Ala, D-Glu, L-Lys or M-DAP, and D-Ala-D-Ala onto UDPMurNAc.  This 
sequence is catalyzed by a series of ATP-dependent ligases MurC-F to form the 
precursor UDPMurNAc-pentapeptide.  The pentapeptide then forms lipid I when 
it is transferred onto a lipid carrier undecaprenyl phosphate catalyzed by the 
enzyme bacterial translocase Ior MraY.  Lipid II is subsequently formed when the 
product of MraY is tailored by the addition of a GlcNAc sugar onto the 4′-hydroxyl 
or MurNAc catalyzed by the enzyme MurG.  The lipid-linked intermediate is then 
transported across the cytoplasmic membrane to the periplasm.  Lipid II then 
undergoes transglycosylation to form a polysaccharide that is cross-linked by 
transpeptidation.  The transglycosylation releases the undecaprenyl 
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pyrophosphate and then recycles it by means of dephosphorylation and “flipped” 
back to the cytoplasm to serve as a substrate for MraY (13) (Fig. 1.2).   
 
 
 
Figure 1.2  Step wise biosynthesis of the peptidoglycan cell wall within gram-
positive and gram-negative bacteria.  This residue is either an L-lysine in gram-
positive bacteria or diaminopimelic acid in gram-negative bacteria. 
 
 
1.2 Translocase I inhibitors 
 
A key step in the biosynthesis of the peptidoglycan cell wall is the transfer of 
phosphor-N-acetylmuramic acid pentapeptide from UDP-N-acetylmuramic acid 
pentapeptide to undecaprenyl phosphate catalyzed by the enzyme MraY (Fig. 
1.3)(19-21).  The integral ten transmembrane, α-helical protein is ubiquitious  
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within bacteria, and lacks any mammalian homolog thus making it an ideal target 
for antibacterial compounds.  However, while the identity of MraY was revealed 
in 1993, lack of tertiary structure and the refractory nature to overexpression and 
purification to homogeneity of this protein has rendered biochemical studies to be 
very difficult (13, 22).   Fortunately, a small amount of Bacillus subtilis MraY has 
been purified to homogeneity and crude extracts of MraY from Escherichia coli 
and Stapylococcus aureus, have been obtained.  Comparative analysis of the 
enzymes reveals five cytoplasmic and six perplasmic conserved domains.  
Alignment of the MraY cytoplasmic domains from E. coli, B. subtilis, and S. 
aureus maintain multiple highly conserved residues including three strictly 
conserved aspartic acid residues (Asp-115, Asp-116, and Asp-267) which may 
form the active site of the enzyme (23, 24).  
 
 
 
Figure  1.3. Enzymatic activity of the translocase I enzyme MraY.  The Mg2+ 
dependent reaction initiates the phosphor-transfer of UDP-N-acetylmuramic acid 
to the isoprenoid unit embedded within the lipid wall subsequently forming UMP 
and lipid I. 
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Despite the difficulty associated with studying MraY, several screens over the 
past decade have discovered several classes of natural product antibiotics which 
have shown to inhibit MraY. Tunicamycins, mureidomycins, liposidomycin, 
muraymycin, capuramycin, and caprzamycin are examples of the classes of 
antibiotics which contain a uridine-like moiety with a high carbon furanoside (Fig. 
1.4).  Highlighted by a uridine disaccharide extended by a fatty acyl chain, the 
tunicamycins consist of one family of reversible, competitive MraY inhibitors.    
However, due to inhibition of GlcNAc-1-P transferase in glycoprotein 
biosynthesis, tunicamycins are toxic to mammals (25).   
 
Two distinct classes of uridine-containing MraY inhibitors are the peptidyl 
nucleoside products mureidomycins and the liposidomycins.  Mureidomycins 
contain a 3ʹ′-deoxyuridine sugar moiety and are highlighted by a unique peptide 
chain that is attached by means of an unusual enamide linkage.  The peptide 
chain includes an N-methyl 2,3-diaminobutyric acid reside as well as a urea 
linked to a C-terminal aromatic amino acid of meta-tyrosine, Trp, or Phe.   These 
slow binding inhibitors are believed to act by binding to the Mg2+ cofactor-binding 
site of MraY at the amino terminus (20).  The liposidomycins consist of a sulfated 
aminoglycoside and fatty-acyl residues bonded to the uridine-containing core. 
These slow binding inhibitors show moderate activity against solubilized E. coli 
MraY.  However, synthetic analogs of these compounds appear more promising 
due to better activity and increased spectrum of antibacterial activity (14, 19).   
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The muraymicyms represent another family of MraY inhibitors that contain an 
aminoribofuranoside monosaccharide connected to a peptide chain, that has an 
unusual urea linked to a C-terminal amino acid.  These potent inhibitors show 
promising antibacterial activity against drug-resistant strains of S. aureus and 
Enterococci.  Synthetic analogues of these compounds, which lack the 
aminoribofuranoside, have reduced in vitro activity, but retain some antibacterial 
activity (19, 26).    The final two classes, the caprazamycin and capuramycin-
related compounds, also inhibit the translocase I enzyme MraY and are the 
classes focused on in this dissertation (21). 
 
 
Figure 1.4.   Families of known translocase I MraY inhibitor compounds. 
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1.2.1. Caprazamycin-related compounds 
The liponucleoside antibiotics of the caprazamycin-related compounds show in 
vitro activity against gram-positive bacteria with no significant toxicity unlike 
tunicamycin, thus showing high potential as antibacterial compounds (27).  
Discovered in 2003 by specific enzymatic screening for MraY translocase I 
inhibition, the caprazamycin structure was established shortly thereafter in 2005 
(28, 29).  The core skeleton consists of an N-alkylated 5′-(β-O-aminoribosyl)-
glycyluridine which is shared with that of closely related liposidomycins also 
shown to inhibit the formation of lipid I by inhibiting MraY translocase I (Fig. 1.5) 
(13, 30).   
 
 
 
Figure 1.5.  Nucleosid antibiotics of the translocase I inhibitor family 
highlighting the N-alkylated 5′-(β-O-aminoribosyl)-glycyluridine core.  (A) 
The caprazamycin family of the MraY translocase I inhibitor family.  (B) The 
liposidomycin family of the MraY translocase I inhibitor family. 
A	  
B	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1.2.2  Capuramycin-Related Compounds 
The capuramycin analogs, also containing a uridine core with a high carbon 
furanose, show potent MraY translocase I inhibition with IC50 values within 10-20 
nm.  In contrast to the caprazamycin-related compounds, the capuramycin-
related compounds are highlighted by a 5ʹ′-C-carbamoyluridine (CarU) core with 
an unusual unsaturated hexose attached via a glycosidic bond (19, 31).  Initially 
discovered in 1986 by generic antibacterial activity screens, the specific analogs 
A-503083 and A-500359 were identified by specific enzymatic screens to identify 
inhibitors of MraY translocase I (Fig. 1.6) (31-34).   
 
  
 
 
Figure 1.6.  Nucleoside antibiotics of the translocase I inhibitor family 
highlighting the 5′-C-carbamoyluridine. 
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SANK 62799, and A-102395 isolated from Amycolatopsis sp. SANK 60206 (Fig. 
1.7).  All four compounds were discovered using an assay for identification of 
MraY activity in vitro and therefore are potential leads as antibiotics that target 
peptidoglycan cell wall biosynthesis (31, 35-37). 
 
 
 
 
Figure 1.7.   MraY translocase I inhibitor compounds discussed in this 
dissertation. 
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the compounds contains an aminoribosyl moiety attached by means of a 5ʹ′-O-
glycosidic bond to a 5ʹ′-C-glycyluridine moiety.  The putative open reading frames 
(orfs) shared within these clusters include those encoding a nonheme, Fe(II)-
dependent dioxygenase (LipL), a putative nucleotidylyltransferase (LipM), a 
glycosyltransferase (LipN), an aminotransferase (LipO), a uridine phosporylase 
(LipP), and a serine hydroxymethyltransferase (LipK) hypothesized to form the 
5ʹ′-C-glycyluridine (GlyU) core.  Prior studies in our group have revealed LipL as a 
nonheme, Fe(II)-dependent dioxygenase converting UMP to uridine-5ʹ′-aldehyde 
(UA), LipO as an L-methionine:UA aminotransferase utilizing UA as a substrate, 
LipP as a low specificity phosphorylase, LipM as a primary amine-requiring 
nucleotidylyltransferase, and LipN as a 5-amino-5-deoxyribosyltransferase (Fig. 
1.8) (38, 39).  However, while five of the six shared genes have been shown to 
form the aminoribosyl moiety of the final compound, the putative serine 
hydroxymethyltransferase (SHMT) and its activity in forming the GlyU core was 
still in question.   
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Figure 1.8.  Biosynthesis of the disaccharide-containing nucleoside core of 
lipopeptidyl nucleoside antibiotics. Enzymes in blue have been functionally 
assigned.  
 
 
Comparative bioinformatic analysis of the genes required for the formation of the 
caprazamycin-related compounds and the capuramycin-related compounds A-
503083 and A-102395 revealed all of the clusters contain the orfs encoding the 
non-heme, Fe(II)-dependent α-ketoglutarate: UMP dioxygenase (LipL) as well as 
the putative SHMT. Gene deletion of the orf encoding the putative SHMTs from 
the biosynthetic gene clusters responsible for forming the caprazamycin-related 
compounds caused a failure to synthesize the final compound.  Recently our lab 
has revealed the necessity of the putative SHMT within the biosynthetic pathway 
of A-102395 by showing the abolishment of production upon gene inactivation 
(27, 31, 35, 40).   The lack of any detectable product formation without the 
presence of the putative SHMT within the biosynthetic gene cluster indicates 
necessity of the enzyme for biosynthesis.  Also, the shared LipL homolog 
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amongst the biosynthetic gene clusters suggests that the UA product formed by 
LipL and its homologs is a shared intermediate and may be a precursor substrate 
for the putative SHMTs.  These similarities prompted us to investigate the 
function of the putative SHMT and to define its role in the biosynthesis of the 
caprazamycin and capuramycin-related compounds. 
 
The canonical SHMT is known primarily for its function in DNA biosynthesis by 
the inter-conversion of Ser and tetrahydrofolate (THF) to Gly and N5, N10-
methylene-THF.  However, the compound N5, N10-methylene-THF is known to be 
the donor of a single carbon group for use not only in thymidine biosynthesis, but 
also can be oxidized by to form the methenyl incorporated into purine 
biosynthesis, or be reduced to form the methyl group donated to sulfur during 
methionine biosynthesis (41, 42).   
 
The formation of the single carbon donor N5, N10-methylene-THF is primarily 
dependent on the SHMT.  The essential role of SHMT has spawned numerous 
reports describing the biochemistry, structure, and mechanism of this enzyme.  
Under the umbrella of the B6-dependent (or PLP) enzymes, the SHMT is 
classified as a member of the type I fold, or α-family.  This particular enzyme 
initiates a reaction by formation of an internal aldimine by binding a key Lys 
residue with the co-factor pyridoxal-5ʹ′-phosphate (PLP) which enables Ser to 
bind to PLP forming an external aldimine.  The β-hydroxyl group is then 
deprotonated by a general base of the enzyme initiating an electron 
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rearrangement utilizing the PLP as an electron sink and forming formaldehyde 
and a Gly bound PLP product.  The formaldehyde group is then incorporated 
onto THF in a series of reactions forming N5, N10-methylene-THF (Fig. 1.9) (4, 
43). 
 
While the in vivo role of canonical SHMTs in transferring the Cβ of Ser to THF is 
well established, several studies have revealed that these SHMTs are also able 
to catalyze numerous reactions in the absence of THF.  Decarboxylation, 
transamination, retroaldol cleavage, and racemization reactions have all been 
seen at rates sometimes approaching or even surpassing those of physiological 
reactions when THF is absent (44, 45).  These in vitro studies of SHMTs raise 
interesting questions about the role that the putative SHMTs play in the 
biosynthesis of MraY inhibitors. 
 
Another enzyme of great interest due to its similarity to the canonical SHMT is L-
threonine aldolase (LTA or LTAE).  Also a type I fold PLP dependent enzyme, 
the canonical LTA catalyzes the interconversion of L-Thr to Gly and 
acetaldehyde.  SHMT and LTA share similar catalytic properties and are able to 
catalyze similar reactions including the retroaldol cleavage of varying L-3-
hydroxyamino acids, the transamination and the racemization of D- and L-alanine, 
and the exchange of the α-proton of Gly with solvent.  While both enzymes show 
similar enzymatic activity, LTA and SHMT appear to have modest specificity for 
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the retroaldol cleavage of L-allo-threonine and the Cβ of serine to H4PteGlu 
respectively (4, 46).   
 
Due to the intriguing chemistry catalyzed by SHMTs and LTAEs, including the 
alternative reactions observed, we set out to establish the putative SHMTs 
function within the biosynthetic gene clusters of the caprazamycin and 
capuramycin-related compounds.  We envisioned that the results would not only 
provide a definitive biosynthetic pathway of the known MraY inhibitor 
compounds, but also serve as a genetic fingerprint for identifying future 
antibiotics.  
 
 
 
Figure 1.9.  Reaction mechanism of the canonical SHMT utilizing Ser and 
THF as substrates in the transfer of a single carbon unit. 
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1.3.  Aims of this study 
 
The overarching objective of this study is to identify the enzymatic activity of the 
putative SHMT shared among the A-90289, muraminomicin, A-102395, and A-
503083 biosynthetic gene clusters of the caprazamycin and capuramycin- related 
compounds. We hypothesize d that these SHMT-like enzymes catalyze a PLP 
dependent aldol-like condensation reaction incorporating the amino acid Gly onto 
the known intermediate UA.  This C-C bond formation would enable the 
elongation of the furanoside and formation of the intermediate GlyU. 
 
To interrogate this hypothesis, three specific aims were developed. 
Aim I:  Isolation and purification of SHMT.  This objective was achieved by 
cloning of the gene, confirming the identity by sequencing, obtaining soluble 
protein from a heterologous host, and optimizing the purification process.  
 
Aim II:  Functional characterization of the putative SHMT.  Characterization of the 
putative SHMT would lead to identification of the enzymatic role played in the 
biosynthesis of the final compounds.  This role can also reveal novel chemistry 
associated with C-C bond formation necessary in more complex antibacterial 
compounds.  This objective was achieved by identifying required co-factors, 
determining viable substrates, identification of the putative SHMT product, and 
optimization of reaction conditions for kinetic analysis of the enzymatic activity. 
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Aim III:  Verification of the expected activity of the putative SHMT in vivo.   Due to 
the novel chemistry associated with the putative SHMT and its preferred 
substrates, identification of specific amino acids in vivo verifies the enzymatic 
activity and necessity in C-C bond formation and the development of the high 
carbon furanoside in caprazamycin and capuramycin-related antibacterial 
biosynthesis.  This task was accomplished by feeding isotopically enriched Gly 
and L-Thr precursosrs to the producing strain of A-503083 and identifying 
incorporation into the CarU core. 
 
The canonical SHMT and LTA were used to compare with the newly 
characterized putative SHMT from the caprazamycin and capuramycin-related 
biosynthetic gene clusters.  The results described here reveal new mechanistic 
information for all three groups of enzyme catalysts.
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Chapter Two 
Materials and Methods 
 
2.1  Chemicals.  
L-Thr [(2S,3R)-2-amino-3-hydroxybutyric acid], D-Thr [(2R,3S)-2-amino-3-
hydroxybutyric acid], L-allo-Thr [(2S,3S)-2-amino-3-hydroxybutyric acid],DL-allo-
Thr,N-methyl-L-Thr, O-phospho-L-Thr, proteinogenic amino acids, uridine-5'-
monophoshate (UMP), uridine, α-ketoglutartate (αKG),β-nicotinamide adenine 
dinucleotide (β-NAD+), potassium-activated aldehyde dehydrogenase (ADH) from 
baker’s yeast, 2,4-dinitrophenylhydrazone (DPNH), tetrahydrofolic acid (THF), 
pyridoxal-5’-phosphate (PLP), various aldehyde substrates, and buffers were 
purchased from Sigma. Synthetic oligonucleotides were purchased from 
Integrated DNA Technologies.  DNA sequencing was performed using the 
BigDye™Terminator version 3.1 Cycle Sequencing kit from Applied Biosystems, 
Inc. (Foster City, CA) and analyzed at the University of Kentucky Advanced 
Genetic Technologies Center. 
 
2.2  Instrumentation. 
UV/Vis spectroscopy was performed with a Bio-Tek µQuant microplate reader 
using Microtest™ 96-well plates (BD Biosciences) or a Shimadzu UV/Vis-1800 
Spectrophotometer equipped with a TCC-240A thermoelectrically temperature 
controlled cell holder.  PCR was performed with a Veriti® 96-well thermal cycler 
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from Applied Biosystems. Analytic HPLC was performed with one of three 
systems: an Agilent 1200 Series Quaternary LC system equipped with a diode 
array detector and an Eclipse XDB-C18 column (250mm x 4.6 mm, 5 µm), a 
Dionex Ultimate 3000 Focused separation module (Bannockburn, IL) equipped 
with a DAD-3000 (RS) and MWD-3000 (RS) diode array detector and an Acclaim 
120 C-18 column (4.6 mm x 100 mm, 3 µm), or a Waters Alliance 2695 
separation module (Milford, MA) equipped with a Waters 2998 diode array 
detector and an analytical Apollo C-18 column (250 mm x 4.6 mm, 5 µm) 
purchased from Grace (Deerfield, IL). 
 
Semipreparative HPLC was performed with a Waters 600 controller and pump 
(Milford, MA) equipped with a 996 diode array detector, 717plus autosampler, 
and an Apollo C-18 column (250 mm x 10 mm, 5 mm) purchased from Grace 
(Deerfield, IL). LC-electrospray ionization (ESI)-mass spectroscopy (MS) was 
performed using an Agilent 6120 Quadrupole MSD mass spectrometer (Agilent 
Technologies, Santa Clara, CA) equipped with an Agilent 1200 Series 
Quaternary LC system and an Eclipse XDB-C18 column (150mm x 4.6 mm, 5 
mm, 80Å).High resolution (HR)-MS was performed at the Department of 
Chemistry Mass Spectrometry Service Laboratory, University of Minnesota, using 
a Bruker BioTOF II.  NMR data were collected using a Varian Unity Inova 400 or 
500 MHz spectrometer (Varian, Inc., Palo Alto, CA) or a Bruker AVANCE 500 
MHz spectrometer (Bruker Biospin Corporation, Billerica, MA). 
	  
22 
2.3  Enzymes, strains, and growth media. 
 Escherichia coli JM109 was purchased from Takara Bio Inc. (Shiga, Japan). 
Restriction enzymes and DNA modifying enzymes were purchased from Takara 
Bio Inc. or New England BioLabs Inc. (Ipswich, MA).  Proteases and nucleases 
for genomic DNA preparation were purchased from Sigma-Aldrich. Media, growth 
conditions, genomic DNA isolation, and recombinant DNA techniques for E. coli 
(31) and actinomycetes (32) were performed as described. Streptomyces 
avermitilis ATCC 31267 and Streptomyces coelicolor A3(2) ATCC BAA-471 were 
obtained from the American Type Culture Collection (ATCC). Streptomyces 
griseus IFO13350 was obtained from the Institute of Fermentation, Osaka (IFO). 
Saccharopolyspora erythraea NRRL 3887 and Streptomyces sp. NRRL 30471 
were obtained from the Agricultural Research Service Culture Collection (NRRL). 
Streptomyces lividans TK21 was a gift from the John Innes Centre. Streptomyces 
albus was a gift from Prof. José A. Salas, Universidad de Oviedo. The remaining 
strains are part of the culture collection maintained at Daiichi-Sankyo Co., Ltd. 
 
A-503083 B and A-503083 F were isolated from Streptomyces sp. SANK 62799 
and purified as previously reported (31).  Muraminomicin F was isolated as 
previously described (47).  MS and 1H-and 13C-NMR spectra (Fig. 2.1) were 
consistent with this report. 
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1H-NMR in DMSO-d6
 
13C-NMR in DMSO-d6
 
Figure 2.1.  1H-and 13C-NMR spectra of muraminomicin F. 
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2.4  Synthesis of 5'-C-glycyluridinediastereomers. 
The synthesis of (5S,6S)-5'-C-glycyluridine, (5R,6S)-5'-C-glycyluridine, and 
(5S,6R)-5'-C-glycyluridine is reported in detail elsewhere (36). ESI-MS analysis 
of (5S,6S)-5'-C-glycyluridineyieldedan [M+Na]+ion of m/z = 340.1, consistent with 
the expected molecular formula of C11H15N3O8Na . NMR spectroscopic 
analysis was obtained at neutral pH (zwitterionic form).  1H-NMR(600 MHz, D2O, 
35 °C): δ = 4.30 (d, J = 3.1 Hz, 1 H, 6'-H), 4.40 (dd, J = 5.7 Hz, J = 1.5 Hz, 1 H, 
4'-H), 4.45 (dd, J = 5.7 Hz, J = 5.3 Hz, 1 H, 3'-H), 4.48 (dd, J = 5.3 Hz, J = 3.7 
Hz, 1 H, 2'-H), 4.64 (dd, J = 3.1 Hz, J = 1.5 Hz, 1 H, 5'-H), 6.00 (d, J = 8.2 Hz, 1 
H, 5-H), 6.05 (d, J = 3.7 Hz, 1 H, 1'-H), 8.16 (d, J = 8.2 Hz, 1 H, 6-H). 13C-
NMR(126 MHz, D2O, 35 °C): δ = 60.04 (C-6'), 69.36 (C-5'), 72.85 (C-3'), 75.85 
(C-2'), 87.57 (C-4'), 92.43 (C-1'), 104.81 (C-5), 144.47 (C-6), 154.09 (C-2), 
168.59 (C-4), 173.35 (C-7')  
 
2.5  Cloning of genes for heterologous expression.  
Genes were amplified by PCR using Expand Long Template PCR System from 
Roche (Indianapolis, IN) with supplied Buffer 2, 200 mM dNTPs, 5% DMSO, 10 
ng DNA template, 5 U DNA polymerase, and 200 nM each of the following primer 
pairs: EcglyA (forward) 5'-
GGTATTGAGGGTCGCATGTTAAAGCGTGAAATGAACATTG-3'/ (reverse) 5'-
AGAGGAGAGTTAGAGCCTTATGCGTAAACCGGGTAACG -3'; EcLTA (forward) 
5'-GGTATTGAGGGTCGCATGTCCGTGCTGGGGCGG-3'/ (reverse) 5'-
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AGAGGAGAGTTAGAGCCTTAACGCGCCAGGAATGCAC-3'; lipK (forward) 5'-
GGTATTGAGGGTCGCATGACGGTGGGGGCTGGTG-3'/ (reverse) 5'-
AGAGGAGAGTTAGAGCCTCACAGCCCGGCCTCCACTT-3'; orf25 (forward) 5'-  
GGTATTGAGGGTCGCATGACTGACACTAACGAGTTACGG -3'/ (reverse) 5'- 
AGAGGAGAGTTAGAGCCTCATGGGTAATCGACGAAGTGGAA -3';  capH 
(forward) 5'-GGTATTGAGGGTCGCATGACTGATATCAGGGAGCTCCGCAAG-
3'/ (reverse) 5'-
AGAGGAGAGTTAGAGCCTCAGGAGAACTCGACGAAATAGAAGGGAG-3'; and 
Mra14 (forward) 5'- 
GGTATTGAGGGTCGCAGCTAGTGGCAAGACATCTTTGGGCG-3'/ (reverse) 5'- 
AGAGGAGAGTTAGAGCCTTGTAGAAGTCGGAACCCAGTGGCAGTG-3'.  DNA 
templates for PCR cloning were E. coli DH5α genomic DNA for EcglyA and 
EcLTA, cosmid pN1 for lipK (48), cosmid pNCap02 for orf25, cosmid pMra02 for 
Mra14, and cosmid N-4 for capH (49). The PCR program included an initial hold 
at 94 °C for 2 min, followed by 30 cycles of 94 °C for 10 s, 56 °C for 15 s, and 68 
°C for 60s per kb DNA. The gel-purified PCR product was inserted into pET-30 
Xa/LIC using ligation-independent cloning as described in the provided protocol 
to yield pET30-EcglycA, pET30-EcLTA, pET30-lipK, pET30-orf25, pET30-mra14, 
and pET30-capH. The genes were sequenced to confirm PCR fidelity. 
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2.6  Site-directed mutagenesis.  
A K235A point mutation of LipK was generated by PCR amplification using 
pET30-lipK as a template and the Expand Long Template PCR system 
(RocheAppliedScience).  Reactions were performed using the manufacturer's 
provided Buffer 2 with 5% DMSO, primers of 5'-
CTTCGGCGGATCGACTCACGCGTCCTTCCCCGGGCCCC-3' and the reverse 
complement (the engineered Ala codon is underlined), and a PCR program 
consisting of an initial hold at 94°C for 2 min followed by 20 cycles of 94°C for 
10s, 56°C for 20s, and 68°C for 7min.  The template DNA was digested with 10 
units of DpnI (NewEngland Biolabs) for 1h at 37°C and transformed into E.coli 
NovaBlue competent cells.  The introduction of the correct point mutation and the 
sequence of the entire gene including 200bp upstream and downstream were 
confirmed by DNA sequencing to yield pET30-lipK (K235A). 
 
2.7  Heterologous production of proteins in E. coli.  
Plasmids pET30-EcglycA and pET30-Eclta, were introduced into E. coli 
BL21(DE3) cells, and the transformed strains were grown in LB supplemented 
with 30 mg/mL kanamycin. Following inoculation of 500 mL of LB with 30 mg/mL 
kanamycin, the cultures were grown at 18 °C until the cell density reached an 
OD600~ 0.5 when expression was induced with 0.1 mM IPTG. Cells were 
harvested after an overnight incubation at 18 °C and lysed in 100 mM Tris-HCl 
(pH 8) and 300 mM KCl using a French Press with one pass at 15000 psi. 
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Following centrifugation the protein was purified using affinity chromatography 
with Ni-NTA agarose from Qiagen (Valencia, CA), and the recombinant proteins 
were desalted into 50 mM phosphate (pH 7.5)(for EcGlyA and EcLTA), 100 mM 
KCl, and 5 % glycerol using a PD-10 desalting column (GE Healthcare). The 
purified protein was concentrated using an Amicon Ultra 10000 MWCO 
centrifugal filter (Millipore) and stored as glycerol stocks (40%) at -20 °C. Protein 
purity was assessed by 12% acrylamide SDS-PAGE; His6-tagged proteins were 
utilized without further modifications. Protein concentration was determined using 
Bradford protein assay or extension coefficients calculated using the ProtParam 
tool available from ExPASY (LipK, ε280= 28,880 M-1cm-1; CapH, ε280= 30,940 
M-1cm-1; EcGlyA, ε280= 46,300 M-1cm-1; EcLTA, ε280= 36,900 M-1 cm-1.   
 
2.8  Subcloning and expression in Streptomyces lividans TK-64 or 
Streptomyces albus.   
Plasmids pET30-lipK, pET30-lipK(K235A), pET30-orf25, and pET30-mra14 were 
digested with NdeI-HindIII and the DNA fragment of the expected size was 
purified and ligated to the identical sites of pUWL201pw to yield pUWL201pw-
lipK, pUWL201pw-lipK(K235A), pUWL201pw-capH, pUWL201pw-orf25, and 
pUWL201pw-mra14  respectively. The resulting plasmids were transformed into 
S. lividans TK-64 using PEG-mediated protoplast transformation and plated on 
M2CaO or R2YE. After 14 h at 28 °C, the plates were overlaid with 1 mL of water 
supplemented with 200 mg of thiostrepton. Single colonies were transferred to 
fresh M2CaO or R2YE plates supplemented with 10 mg/mL thiostrepton, and 
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after 4 days at 28 °C positive transformants were confirmed by colony PCR using 
InstaGene Matrix from Bio-Rad (Hercules, CA) and LA-Taq polymerase with GC 
buffer II from Takara Bio Inc. (Shiga, Japan).  
 
The recombinant strain was utilized to inoculate 50 mL R2YE containing 10 
µg/mL thiostrepton, grown for 2 days at 28 °C at 250 rpm, and 2 mL transferred 
to fresh 100 mL containing 10 µg/mL thiostrepton. Following growth for 3 days at 
28 °C at 250 rpm, the cells from 400 mL of culture were collected by 
centrifugation and washed with 60 mL of 100 mM potassium phosphate (pH 7.4), 
300 mM KCl, and 1 mM PMSF and stored on ice for 10 min. Following 
centrifugation at 4,000 rpm for 15 min at 4oC,the pellet was thoroughly 
resuspended in 60 mL ice-cold 100 mM potassium phosphate (pH 7.4), 300 mM 
KCl, and 1 mM PMSF and ~25 mg of lysozyme was subsequently added to the 
suspension. After incubation on ice for 30 minutes, the suspension was mixed by 
pipeting and subjected to one pass through a French press at 18,000 psi. The 
cell debris was removed by centrifugation (17,500 rpm for 45 min), the cell-free 
extract filtered using a 0.45 mm PVDF syringe filter, and the clarified extract was 
loaded onto a gravity column containing 0.5 mL Ni-NTA resin that was pre-
equilibrated with 100 mM potassium phosphate (pH 7.4) containing 300mM KCl. 
The resin was washed with 10 volumes 100 mM potassium phosphate (pH 7.4) 
containing 300 mM KCl followed by 10 volumes of 100 mM potassium phosphate 
(pH 7.4) containing 300 mM KCl and 20 mM imidazole. The His6-tagged protein 
was eluted with 10 volumes of 100 mM potassium phosphate (pH 7.4) containing 
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300 mM KCl and 250 mM imidazole and concentrated to < 2.5 mL using an 
Amicon Ultra 10k MWCO. The sample was desalted into 35 mM potassium 
phosphate (pH 7.4) containing 100 mM KCl using a gravity flow PD-10 column 
following the manufacturer’s instructions. The purified protein was re-
concentrated and stored as a 40% glycerol stock at -20°C. 
 
 
2.9  Subcloning and expression of CapH into S. lividans TK-64.  
Plasmid  pET30-CapH was  digested with NdeI-HindIII and the DNA fragment of 
the expected size was purified and ligated to the identical sites of pUWL201pw to 
yield pUWL201pw-CapH. The resulting plasmids was transformed into S. lividans 
TK-64 using PEG-mediated protoplast transformation and plated on M2CaO agar 
plates. After 16 hr at 28 °C, the plates were overlaid with 1 mL of nutrient agar 
supplemented with 200 mg of thiostrepton. Single colonies were transferred to 
fresh M2CaO plates supplemented with 25mg/mL thiostrepton, and after 4 days 
at 28 °C positive transformants were confirmed by colony PCR using InstaGene 
Matrix from Bio-Rad (Hercules, CA) and LA-Taq polymerase with GC buffer II 
from Takara Bio Inc. (Shiga, Japan).  
 
The recombinant strain was utilized to inoculate 50 mL M2CaO containing 10 
mg/mL thiostrepton, grown for 2 days at 28 °C at 250 rpm, and 2 mL transferred 
to fresh 100 mL containing 10 mg/mL thiostrepton. Following growth for 3 days at 
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28 °C at 250 rpm, the cells from 1000 mL of culture were collected by 
centrifugation at 4,000 rpm for 15 min at 4oC, the pellet was thoroughly re-
suspended in ice-cold and re-suspended with 250 mL of 100 mM potassium 
phosphate pH 7.4, 300 mM KCl and stored on ice. After incubation on ice for 30 
minutes, the cell suspension was mixed by pipeting and subjected to one pass 
through a French press at 18,000 psi. The cell debris was removed by 
centrifugation (17,500 rpm for 45 min), the cell-free extract filtered using a 0.45 
mm PVDF syringe filter, and the clarified extract was loaded onto a gravity 
column containing 0.5 mL Ni-NTA resin that was pre-equilibrated with 100 mM 
potassium phosphate containing 300 mM KCl. The resin was washed with 10 
volumes 100 mM potassium phosphate pH 7.4 containing 300 mM KCl (Buffer A) 
followed by 10 volumes of Buffer A containing 20 mM imidazole. The His-tagged 
protein was eluted with 10 volumes of Buffer A containing 250 mM imidazole and 
concentrated to < 2.5 mL using an Amicon Ultra 10k MWCO. The sample was 
desalted into 35 mM potassium phosphate pH 7.4 containing 100 mM KCl using 
a gravity flow PD-10 column following the manufacturer’s instructions. The 
purified protein was re-concentrated and stored as a 40% glycerol stock at -20 
oC. 
 
2.10  HPLC analysis of the reactions catalyzed by LipK, CapH, Orf 25, and 
Mra14.  Routine reactions for LipK, CapH, Orf25, and Mra14 consisted of 50 mM 
HEPES or TES (pH 7.5), 2 mM UA, 5 mM co-substrate, 0.1 mM PLP, and 3.5 
mM LipK at 30 °Cat the indicated time points. Following removal of the protein by 
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ultrafiltration or TCA precipitation (7%), the reaction components were analyzed 
using reverse-phase chromatography using the Agilent 1200 series HPLC 
equipped with an Eclipse XDB-C18 column or a Dionex Ultimate 3000 Focused 
separation module (Bannockburn, IL) equipped with a DAD-3000(RS) and MWD-
3000(RS) diode array detector and an Acclaim 120 C-18 column (4.6 mm x 100 
mm, 3 mm). A series of linear gradients was developed from 0.1 % TFA in 0.5 % 
acetonitrile (A) to 0.1% TFA in 90% acetonitrile (B) in the following manner 
(beginning time and ending time with linear increase to % B): 0-8 min, 100% B; 
8-28 min, 100% B; 28-32 min, 100% B; and 32-35 min, 0% B. The flow rate was 
kept constant at 1 mL/min, and elution was monitored at 260 nm. 
 
2.11  Isolation of the LipK product.   
A large scale reaction (33 mL) consisted of 50 mM TES (pH 7.5), 100 mM KCl, 
0.1 mM PLP, 1 mM DTT, 10 mM L-Thr, 2.5 mM uridine-5’-aldehyde, 3 mM NAD, 
10 U ADH, and 5 mM LipK. Following incubation for 24 h at 30 °C, protein was 
removed by ultra filtration and the product was partially purified by HPLC using a 
C-18 reverse-phase semi-preparative column. A series of linear gradients was 
developed from A to B in the following manner (beginning time and ending time 
with linear increase to % B): 0-4 min, 100% B; 4-24 min, 50% B; 24-26 min, 
100% B; 26-32 min, 100% B; and 32-35 min, 0% B. The flow rate was kept 
constant at 3.5 mL/min, and elution was monitored at 260 nm. Fractions 
containing the desired product eluting near the column void volume were 
combined and lyophilized to yield a viscous, clear solution. The amount of 
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product was estimated using 262 nm = 10,100 M-1 (50). Partially purified GlyU 
was resuspended in 5 mL of 200 mM ammonium acetate (pH 8.8) and loaded 
onto a column containing 1 mL of immobilized boronic acid resin (Thermo-Fisher) 
that was equilibrated in 10 mL of 200 mM ammonium acetate (pH 8.8). Following 
a 3 mL wash with the same buffer, the bound GlyU was eluted with 12 mL of 0.1 
M formic acid. The purified sample was lyophilized prior to spectroscopic 
analysis. 
 
2.12  Phosgene modification of GlyU.   
Phosgene modification of β-hydroxy-α-amino acids was carried out as previously 
described (51). Approximately 20 mg of partially purified GlyU was dissolved in 1 
M potassium hydroxide (6.5 mL), and the solution cooled to 5°C prior to the 
addition of 6 mL of a 20% solution of phosgene in toluene. Following 5 min with 
rigorous stirring, the mixture was acidified with 10 drops of concentrated HCl, and 
the aqueous phase was removed and subjected to HPLC for purification using a 
C-18 reverse-phase semi-preparative column following the above conditions. The 
purified product was lyophilized and subjected to spectroscopic analysis.  1H-
NMR (D2O, 500 MHz): δ7.56 (d, J= 8.5 Hz, 1H), 5.95 (d, J= 5.0 Hz, 1H), 5.90 (d, 
J= 8.0 Hz, 1H), 5.08 (dd, J= 5.0 Hz,J= 2.5 Hz,1H),4.55 (d, J= 5.5Hz, 1H), 4.45 (t, 
J= 5.25Hz, 1H),4.41 (t, J= 5.0Hz, 1H), 4.30 (dd, J= 5.25Hz, J= 2.5 Hz,1H). 13C-
NMR (D2O, 100 MHz): δ 173.54, 165.85, 159.98, 151.51, 141.03, 102.60, 89.09, 
83.33, 77.59, 72.71, 69.24, 62.38, 55.83. 
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For analytical analysis of synthetic GlyU diastereomers, a 2 mM solution (50 mL) 
of pure diastereomer was prepared and chilled on ice for 5 min. After addition of 
10 mL of 5 M KOH, the reaction was initiated by adding 50 mL of 20% phosgene 
in toluene. After a 1 h incubation on ice with periodic mixing, the organic phase 
was removed and the aqueous phase analyzed by HPLC using the Agilent 1200 
series HPLC Agilent 1200 Series equipped with an Eclipse XDB-C18 column and 
gradient conditions described above for isolation of the LipK product. 
 
2.13  Modification of aldehydes with DPNH.   
LipK reaction components were modified with DPNH as previously described 
(52). Following protein removal by centrifugation, the modified components were 
analyzed using reverse-phase chromatography using the Agilent 1200 series 
HPLC Agilent 1200 Series equipped with an Eclipse XDB-C18 column. A series 
of linear gradients was developed from A to B in the following manner (beginning 
time and ending time with linear increase to % B): 0-8 min, 100% B; 8-28 min, 
100% B; 28-32 min, 100% B; and 32-35 min, 0% B. The flow rate was kept 
constant at 1 mL/min, and elution was monitored at 430 nm. 
 
2.14  Kinetic analysis of LipK and CapH.  
Single-substrate kinetic analysis was carried out by monitoring the reduction of β-
NAD+ using ε340= 6220 M-1cm-1. Reaction mixtures (90 mL) consisting of 100 
mM TES (pH 7.5), 100 mM KCl, 1 mM DTT, 30 mM L-Thr, 0.1 mM PLP, 2 mM β-
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NAD, and variable UA (1.0-125 mM) were incubated at 30 oC for 1 min prior to 
initiation with a mixture (10 mL) consisting of 50 mM TES (pH 7.5), 100 mM KCl, 
1 mM DTT, 2 mM β-NAD, 1 U ADH, and 250 nM  LipK or CapH. Reactions were 
carried out for 10 min, and rates were calculated using linear regression analysis 
with data obtained under initial velocity conditions (< 10% product).  Data were 
fitted to the Michaelis-Menten equation using GraphPad Prism 5.0.4 (GraphPad 
Software, Inc., La Jolla, CA). Each data point represents the average of a 
minimum of three independent measurements. 
 
Bi-substrate kinetic analysis for LipK were performed using reactions as 
described above with variable UA (1.0 -60 mM) and L-Thr (62 mM –15.6 mM). 
For mechanistic determination (ping pong versus sequential mechanism) the 
inverse data (1/[S] versus1/v) were analyzed by simple linear regression 
analysis. If data are fitted to an equation (Fig. 2.2; (53)) describing a random 
sequential mechanism as described for serine hydroxymethyltransferases (54), 
the global fit yields a kinetic constant of Km= 31 mM with respect to L-Thr and α= 
0.88 (α is the factor by which the binding of one substrate alters the dissociation 
constant for the remaining substrate; an αvalue of unity indicates substrate 
binding has no effect on the binding of the respective substrate). 
 
1
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Figure 2.2  Equation for simple linear regression analysis. 
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2.15  Isotopic Enrichment.  
Fermentation media and growth conditions for Streptomyces sp. SANK 62799 
were as previously described (31).  A seed culture was incubated at 28 oC for 48 
h when 1.5 mL was used to inoculate fresh media (50 mL liquid medium in a 250 
mL flask). After fermentation for 70 h, 25 mg of filter-sterilized [1-13C]Gly, [2-
13C]Gly, or L-[13C4,15N]Thr was added to each flask. Fermentation was continued 
an additional 72 h. An equal volume of methanol was added directly to the 
culture and mixed vigorously prior to centrifugation to remove cell debris. The 
supernatant was lyophilized and the dried powder was resuspended in water 
(100 mg/mL) for HPLC analysis using a C-18 reverse-phase semi-preparative 
column. A series of linear gradients was developed from A to B in the following 
manner (beginning time and ending time with linear increase to % B): 0-6 min, 
0% B; 6-26 min, 100% B; 26-30min, 100% B; 30-34 min, 0% B; and 34-35 min, 
0% B. The flow rate was kept constant at 3.5 mL/min, and elution was monitored 
at 260 nm.  Relative peak intensities were assigned based on the relative 
intensity of C -2''and C-3'' from the natural abundance spectrum. 
 
2.16  HPLC analysis of the reactions catalyzed by EcGlyA and EcLTA with 
2-pyridinde-carboxaldehyde and L-Thr.   
Routine reactions EcGlyA and EcLTA consisted of 50 mM potassium phosphate 
(pH 7.5), 2 mM 2-pyridine-carboxaldehyde, 5 mM L-Thr, 0.1 mM PLP, and 5.0 
mM EcGlyA or EcLTA at 30 °C for the indicated time points. Following removal of 
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the protein by ultrafiltration, the reaction components were analyzed using 
reverse-phase chromatography using the Dionex Ultimate 3000 Focused 
separation module (Bannockburn, IL) equipped with a DAD-3000(RS) and MWD-
3000(RS) diode array detector and an Acclaim 120 C-18 column (4.6 mm x 100 
mm, 3 mm). A series of linear gradients was developed from 0.1 % TFA in 0.5 % 
acetonitrile (A) to 0.1% TFA in 90% acetonitrile (B) in the following manner 
(beginning time and ending time with linear increase to % B): 0-8 min, 100% B; 
8-28 min, 100% B; 28-32 min, 100% B; and 32-35 min, 0% B. The flow rate was 
kept constant at 1 mL/min, and elution was monitored at 260 nm. 
	  
37 
Chapter Three 
RESULTS and Discussion 
 
3.1. Heterologous expression of putative serine hydroxymethyltransferases 
(SHMT) 
 
The uniqueness of the C-C bond formation involved in SHMT activity and the 
presence of a single putative SHMT within the biosynthetic gene clusters of the 
caprazamycin and capuramycin-related compounds under investigation 
prompted inquiry into the function of these putative enzymes. However, initial 
investigation of the putative SHMTs required the isolation of the initial DNA, 
insertion into the selected vector system, and expression of a soluble protein. 
 
3.1.1 Isolation of the putative SHMTs from cosmid DNA 
Bioinformatic analysis of each of the biosynthetic gene clusters of 
muraminomicin, A-90289, A-503083, and A-102395 previously revealed the 
presence of a putative SHMT within each cluster.  The moderate sequence 
similarity/identity of the putative SHMTs to each suggested a shared function of 
each enzyme in the biosynthesis of the final compounds (Table 3.1).  In order to 
elucidate the function of the putative SHMTs and their mechanism in the 
biosynthesis of the caprazamycin-related and capuramycin-related compounds, 
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we cloned and expressed the genes from cosmid DNA generously provided by 
Daiichi Sankyo Novare. 
 
Primers for amplification of the putative SHMTs for the caprazamycin-related 
compounds muraminomicin and A-90289 were designed from the sequence, and 
the genes of interest were then amplified by PCR from the cosmid DNA pMra02 
and pLip02 respectively.  The putative SHMTs for the capuramycin-related 
compounds A-503083 and A-102395 were amplified form the cosmid DNA N-1 
and NCap02 respectively.  After agarose gel purification, the DNA was then 
inserted into the pET30 Xa/LIC vector and sequentially transformed into 
NovaBlue cells purchased from Novagen.  Individual colonies were then selected 
and grown in a 3.0 mL LB culture containing the antibiotic selection marker 
kanamycin.   The cells were collected and the plasmid was purified.  The gene of 
the purified plasmid was sequenced to ensure 100% identity to the expected 
sequence.   
 
Table 3.1.  Putative SHMT DNA comparison.  Comparison of the DNA 
sequence of the individual putative SHMTs.  %Identical/%Similar. 
	   lipK	   capH	   mra14	   orf25	  
lipK	   X	   54/68	   55/68	   55/79	  
capH	   54/68	   X	   62/64	   81/82	  
mra14	   55/68	   62/64	   X	   62/64	  
orf25	   55/79	   81/82	   62/64	   x	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3.1.2  Protein expression of putative SHMTs  
After sequencing to confirm the identity, the plasmids encoding the putative 
SHMTs were tested for their ability to produce soluble, recombinant protein.  Cell 
lines for  pET30-lipK, pET30- capH, pET30-mra14, and pET30-orf25 were 
created by transformation of each respective vector into E. coli BL21(DE3) cells.  
The cells were then plated and cultured in LB broth with the antibiotic selection 
marker kanamycin.  A one-liter culture was grown for each of the above cell lines 
and gene expression induced with IPTG.  Unfortunately none of the above 
proteins were soluble in the E. coli strain, therefore an alternative expression 
system was chosen.  The pET30 Xa/LIC vectors containing the cloned genes 
were digested with the restriction enzymes NdeI and HindIII to remove the 
putative SHMT genes including the engineered sequence for an N-terminal His6-
tag.  The DNA fragment was then purified by agarose gel electrophoresis, ligated 
into the pUWL201pw vector, and transformed into S. lividans TK64 protoplasts.  
The plasmid encoding the model enzyme LipK was also used to transform a 
different host, Streptomyces albus (S. albus).  The respective S. lividans or S. 
albus strain was then cultured in R2YE media with the selective antibiotic 
thiostrepton and the recombinant proteins were partially purified by nickel affinity 
column (Fig. 3.1A-D and F).  All five proteins proved soluble in S. lividans; LipK 
was also soluble in S. albus.  
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Figure 3.1.  Expression of recombinant putative SHMTs. (A) SDS-PAGE 
analysis of partially purified His6-Orf25 from Streptomyces lividans TK64 (lane 2, 
expected MW of 50.24 kD). (B) SDS-PAGE analysis of partially purified His6-
Mra14 from Streptomyces lividans TK64 (lane 2, expected MW of 50.1 kD). (C) 
SDS-PAGE analysis of partially purified His6-CapH from Streptomyces lividans 
TK64 (lane 2, expected MW of 50.4 kD).  (D) SDS-PAGE analysis of purified 
His6-LipK from Streptomyces lividans TK64 (lane 2, expected MW of 50.1 kD). 
(E) SDS-PAGE analysis of partially purified His6-LipK(K235A) (lane 2, expected 
MW of 50.1 kD).  (F) SDS-PAGE analysis of partially purified His6-LipK from 
Streptomyces albus (lane 2, expected MW of 50.1 kD).  The expected molecular 
weight for each of the above proteins was calculated to include an engineered N-
terminal His6-tag (5 kD) and lane 1 represents molecular weight standards 
purchased from BioRad. 
	  
	  
3.1.3  Site directed mutagenesis of the model enzyme LipK 
Due to the importance of the Lys residue in the formation of the PLP binding 
motif in SHMT reactions, a His6-LipK(K235A) mutant was generated.  PLP 
dependent enzymes follow a mechanistic pathway that can be monitored by 
UV/Vis spectroscopy.  Both the known SHMTs and LTAs involve the formation of 
an internal aldimine (holo-enzyme) upon which an amino acid then binds forming 
an external aldimine.  Both the internal and external aldimine display a unique 
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absorbance at 425 nm. (4, 43)  Mutation of the lysine residue would obliterate 
formation of the PLP bound intermediate and formation of the external aldimine 
to yield an inactive enzyme.  The lipK-(K235A) mutant was generated from 
pET30-lipK using Quikchange technology and sequenced to 100% identity.  The 
lipK-(K235A) plasmid was then digested with NdeI and HindIII and ligated into 
the pUW201pw vector for transformation into S. lividans TK64 protoplasts.  The 
generated LipK(K235A) mutant	  was heterologously expressed in S. lividans TK-
64 and also proved to be soluble (Fig. 3.1E). 
	  
3.2.  Characterization of theoretical SHMTs 
With the soluble proteins in hand, we were able to test for enzymatic activity and 
determine the role of the putative SHMTs in the biosynthesis of icaprazamycin 
and capuramycin-like compounds. Previous work in our lab has indicated that the 
precursor for the putative SHMTs was likely uridine-5ʹ′-aldehyde (UA), the product 
of the α-ketoglutarage:UMP dioxygenase LipL (38).  We hypothesized that these 
enzymes used UA to add a glycyl unit to produce 5ʹ′-C-glycyluridine (GlyU) (Fig. 
3.2).  
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Figure 3.2   Reaction of putative SHMTs in caprazamycin and capuramycin-
related compound biosynthesis.  The formation of GlyU (1) utilizing uridine-5ʹ′-
aldehyde (2) as a substrate and the putative SHMTs.     
	  
	  
	  
3.2.1.1 Substrate and activity testing of the putative SHMTs Mra14, 
LipK, CapH, and Orf25 
In order to test The hypothesized function of the putative SHMTs, we synthesized 
the potential substrate UA (Fig. 3.3) and incubated it with 5 µM of each putative 
SHMT Mra14, LipK, Orf25, and CapH, with Gly, or other L-amino acids as 
potential co-substrates. 
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Figure 3.3.  The substrate Uridine-5′-aldehyde NMR. The synthesis of uridine-
5′-aldehdye  followed a two-step procedure that was previously described.(38) 
MS and 1H- and 13C-NMR spectra (above) were consistent with this report. 
 
 
 
3.2.1.2 Substrates and enzymatic activity of the putative SHMTs from 
caprazamycin-like compounds muraminomicin and A-90289.   
The caprazamycin-related compounds has a core structure of a β-hydroxy-α-
amino acid 5′-C-glycyluridine (GlyU).  Due to the SHMTs C-C bond forming 
ability, the putative SHMTs Mra14 and LipK from caprazamycin-related 
compounds were initially tested for enzymatic activity using UA as well as the co-
factor PLP with the expectation that GlyU would be formed.  Gly and Ser were 
initially tested as glycyl unit donors for incorporation onto the UA intermediate.   
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3.2.1.2a Substrates and enzymatic activity of Mra1  
Enzymatic activity of the putative SHMT Mra14 from the muraminomicin 
biosynthetic gene cluster was tested using 2.0 mM UA, 0.1 mM PLP, and 10.0 
mM of a variety of amino acid donors in 50 mM potassium phosphate buffer (pH 
7.5).  Individual reactions were prepared and incubated at 30°C for 2 hr, 6 hr, and 
18 hr and terminated by spin column filtration.  The reactions were then analyzed 
by reverse-phase HPLC utilizing a linear acetonitrile gradient.  No activity was 
observed with Gly or Ser as amino acid donors.  In contrast, enzymatic activity 
was found using UA and L-Thr as the donor with PLP as a co-factor (Fig. 3.4A). 
3.2.1.2b Substrates and enzymatic activity of LipK 
The putative SHMT LipK from the A-90289 biosynthetic gene cluster was also 
tested for activity using 2.0 mM UA, 0.1 mM PLP, and 10.0 mM of a variety of 
amino acid donors in 50 mM potassium phosphate buffer (pH 7.5). Once again, 
the individual reactions were prepared and incubated at 30°C for 2 hr, 6 hr, and 
18 hr and terminated by spin column filtration and analyzed by reverse-phase 
HPLC utilizing a linear acetonitrile gradient.  Identical to Mra14, the only 
enzymatic activity was seen utilizing UA, and L-Thr as substrates with co-factor 
PLP (Fig. 3.4B).   
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Figure 3.4.  Verification of enzymatic activity of the putative SHMTs isolated 
from the biosynthetic gene cluster of caprazamycin-related compounds.  
Reactions were carried out in 50 mM potassium phosphate buffer (pH 7.5), 
0.1mM PLP, 10 mM L-Thr or Gly, and 2.0 mM UA.  (A)  Enzymatic activity 
involving the putative 5 µM SHMT, Mra14, from the muraminomicin biosynthetic 
gene cluster.  No activity was seen with the amino acid donor Gly while product 
formation was observed at 1.28 min with L-Thr.  (B)  Enzymatic activity involving 
the putative 5 µM SHMT, LipK, from A-90289 biosynthetic gene cluster.  Again, 
no activity was seen with the amino acid donor Gly while product formation was 
observed at 1.28 min with L-Thr.   
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3.2.2 Characterization of enzymatic product using LipK as the model 
enzyme 
HPLC analysis revealed the formation of a new peak, but only with the substrates 
UA, L-Thr, and the cofactor PLP. In contrast incubation of the mutant protein 
LipK(K235A) with UA, L-Thr, PLP, and other amino acids in place of L-Thr 
revealed no new peak.  The lack of activity and utilization of any other amino acid 
donor verifies the specificity of this enzyme mutagenesis of the lysine residue 
indicates the necessity of PLP binding and internal aldimine formation to initiate 
the catalytic mechanism (Fig. 3.5 and Fig. 3.20).  Using a large-scale reaction 
with LipK, the product was partially purified by reverse-phase HPLC.   
Subsequentially, a boronic acid affinity column was utilized to bind the cis-
hydroxyl groups located on the 2ʹ′ and 3ʹ′ positions of the ribose of the expected 
enzymatic product. 
3.2.2.1 LC-MS anaylsis of LipK product 
The purified product was verified for purity by HPLC analysis and submitted for 
LC-MS analysis (Fig. 3.6).  LC-MS revealed a (M – H)-  ion at m/z = 315.9 
consistent with the molecular formula C11H13N3O8 of GlyU (expected m/z = 
316.1) (Fig. 3.6B and Fig. 3.6C).   
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Figure 3.5.  HPLC analysis of the reaction catalyzed by LipK.   Using 2 with 
co-substrate Gly or Ser (I), L-Thr without exogenous PLP (II), L-Thr (III), and L-Thr 
with LipK (K235A) (IV). AU, absorbance units; A260, absorbance at 260 nm. 
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Figure 3.6.  LC-MS analysis of the LipK product, 1. (A) HPLC trace of 
enzymatically prepared product following purification using reverse-phase 
chromatography and boronic acid affinity chromatography. (B) Mass spectrum for 
the peak eluting at t = 3.3 min yielding an (M - H)- ion consistent with the 
molecular formula of 1. (C) High resolution mass spectrum of purified 1 yielding 
an (M - H)- ion consistent with the molecular formula of 1. A260, absorbance at 
260 nm. 
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3.2.2.2 1D and 2D NMR spectroscopic analysis 
Approximatedly 10 mg of purified product was lyophilized and re-suspended in 
DMSO for 1D and 2D NMR analysis.   
3.2.2.2a  1D Spectroscopic analysis 
In an effort to easily identify the 1ʹ′, 5, 5ʹ′, and 2ʹ′ peaks, a DMSO solvent was 
chosen as the solvent (Fig. 3.7).  The spectroscopic analysis is consistent with 
that of the expected product (5'S, 6'S)-GlyU (Fig. 3.7 – 3.9 ) which was compared 
to synthetic NMR data acquired with (5'S, 6'S)-GlyU. 
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Figure 3.7.  1D NMR spectra of the LipK product, 1. (A) 1H-NMR spectrum of 
1 following a two-step purification of reverse-phase chromatography and boronic 
acid affinity chromatography. DMSO was utilized as a solvent to minimize the 
interference of the water peak that was difficult to avoid due to the highly 
hygroscopic nature of 1. (B) 13C-NMR spectrum of 1 with contaminating glycerol 
that originated from the enzyme storage solution and formate that was used to 
elute 1 from the immobilized boronic acid resin. 
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3.2.2.2b   2D Spectroscopic analysis  
 
 
Figure 3.8.  1H-13C gHSQC NMR spectrum of the LipK product, 1. 
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Figure 3.9.  1H-13C gHMBC NMR spectrum of the LipK product, 1. 
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3.2.3 Phosgene modification and HR-ESI-MS, 1D, and 2D spectroscopic 
analysis of the LipK enzymatic product and synthetic controls 
Further stereochemical assignment of the 5' and 6' position of the enzymatic LipK 
product by phosgene modification was done.  Phosgene (COCl2), known 
primarily for its use in WWI as a poisonous choking agent and for its use in 
polyurethane synthesis, has the ability to lock in the stereochemistry of β-
hydroxy-α-amino acids, and therefore compound 1 by reacting with primary 
amine and adjacent oxygen center.  Phosgene initially reacts with the nitrogen 
lone pair forming a collapsible intermediate, which gives a stable carbomoyl 
chloride derivative and can sequentially undergo dehydrohalogenation. 
Reactions with α-amino acids and phosgene afford oxazolidine-2,5-diones, 
commonly called N-carboxy anhydrides or Leuchs’ anhydrides without altering 
the stereochemistry of the original stereocenters of the initial substrate (55, 56). 
 
Synthetic controls of the (5'S, 6'S)-GlyU, (5'S, 6'R)-GlyU, and (5'R, 6'S)-GlyU 
compound were obtained from the lab of Dr. Christian Ducho.  Both the synthetic 
and enzymatic LipK product were modified with phosgene and were then 
analyzed by HPLC and NMR spectroscopy (Fig. 3.10 – 3.14).   
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3.2.3.1  HPLC and MS analysis of phosgene modified 1 controls 
and the LipK enzymatic product 
HPLC analysis of the phosgene-modified compounds revealed identical elution 
times of the phosgene-modified enzymatic product and that of the phosgene 
modified (5'S, 6'S)-GlyU diastereomer (Fig. 3.10).  The new peaks were collected 
and subjected to MS analysis.  The new peaks revealed (M – H)- ions of m/z =  
341.7 and 367.6. These masses are consistent with that of either a single 
phosgene modification (m/z = 343) or a double phosgene modification (m/z = 
369) (Fig. 3.11). 
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Figure 3.10.  Comparative analysis of enzymatic and synthetic 1 
diastereomers. (A) HPLC analysis of pure phosgene-modified (5'S,6'S)-1 that 
was prepared by enzymatic synthesis and confirmed by NMR spectroscopy (I), 
(5'S,6'S)-1 prepared by chemical synthesis (black, solid line) and spiked with an 
equimolar amount of enzymatic (5'S,6'S)-1 (blue, dashed line) (II), crude mixture 
of (5'S,6'S)-GlyU that was prepared by enzymatic synthesis and modified with 
phosgene (III), crude mixture of (5'S,6'S)-1 that was prepared by chemical 
synthesis and modified with phosgene (black, solid line) and spiked with 
authentic, enzymatically produced phosgene-modified (5'S,6'S)-1 (red, dashed 
line) (IV). (B) HPLC analysis of pure phosgene-modified (5'S,6'S)-1 (I), synthetic 
(5'R,6'S)-1 (II), phosgene-modified (5'R,6'S)-1 (III), synthetic (5'S,6'R)-1 (IV), and 
phosgene-modified (5'S,6'R)-1 (V). A260, absorbance at 260 nm. 
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Figure 3.11.  Phosgene modification of 1. (A) Semipreparative HPLC analysis 
of purified 1 prepared enzymatically that was reacted with phosgene to yield two 
major products with the expected mass spectrum for modification with (B) one or 
(C) two molecules of phosgene. A260, absorbance at 260 nm. 
	  
3.2.3.2  1D NMR analysis of the phosgene modified LipK 
enzymatic product 
1H-NMR analysis of the phosgene-modified enzymatic product indicated a J 
coupling  of ~5 Hz which is consistent with the MM2 ChemBio3D prediction 
suggesting a dihedral angle of 112° for phosgene-modified threo diastereomer 
(5'S,6'S)-GlyU under acidic conditions.  In contrast, the erythro diastereomers are 
predicted to contain dihedral angles of ≤32° which is approximate to J values >8 
Hz.  The remaining (5'R, 6'R) threo diastereomer was ruled out due to the 
necessity of the dihedral angle of 160° which correlates to a ~12 Hz coupling 
constant (Fig. 3.12). 
A B 
Formula C12H13N3O9 
m/z = 343.065182 
Formula C13H11N3O10 
m/z = 369.044447 
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Figure 3.12.   1D NMR spectrum of phosgene-modified (5'S,6'S)-1. (A) 1H 
NMR spectrum of (5'S,6'S)-1 prepared enzymatically and modified with 
phosgene. Predictions following MM2 energy minimization with ChemBio3D 
suggest a dihedral angle of 112° for	  phosgene-modified (5'S,6'S)-1 under acidic 
conditions that were utilized to obtain purified material for NMR. This dihedral 
angle is consistent with the J value of 5 Hz obtained from the 1H-NMR spectrum, 
suggesting a threo configuration and overall stereochemical assignment as 
(5'S,6'S)-1. [Note that the ribofuranose component changes the priority at C-5’ 
compared to C-3 of (2S,3R)-Thr, the threo diastereomer of L-Thr that serves as 
the substrate for LipK]. The erythro diastereomers are predicted to have dihedral 
angles of ≤ 32° that would yield J values of > 8 Hz, and the remaining threo 
diastereomer [(5'R,6'R)-1] is predicted to have a dihedral angle of 160° that 
would yield a J value of ~12 Hz. (B) 13C NMR spectrum of (5'S,6'S)-1 prepared 
enzymatically and modified with phosgene. 
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3.2.3.3   2D NMR analysis of the phosgene modified LipK 
enzymatic product 
 
Figure 3.13.  gCOSY NMR spectrum of phosgene-modified (5'S,6'S)-1.  
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Figure 3.14.  1H-13C gHMBC NMR spectrum of phosgene-modified (5'S,6'S)-
1. 
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3.2.4 Identification of enzymatic activity with capuramycin-related 
compounds by HPLC analysis 
Bioinformatic analysis revealed both the caprazamycin and capuramycin-related 
compounds contain lipL and an orf encoding the putative SHMT homolog.  This 
suggests a strong correlation in the biosynthesis of the core structures where 
GlyU is an intermediate of the uridine-5ʹ′--carboxamide (CarU) found in 
capuramycin-related antibiotics.  
3.2.4.1 Substrates and enzymatic activity of Orf25 
The putative SHMT, Orf25, from the capuramycin-like compound A-102395, was 
tested for activity using 2.0 mM UA, 0.1 mM PLP, and 10.0 mM of a variety of 
amino acid donors in 50 mM potassium phosphate buffer (pH 7.5). Individual 
reactions were incubated at 30°C and terminated by spin column filtration at 2 hr, 
6 hr, and 18 hr time points. The control reaction and subsequent reactions 
containing 5 µM of Orf25 were then analyzed by reverse-phase HPLC using a 
linear gradient of water to acetonitrile.  The control reaction containing all the 
components except enzyme showed elution of the UA substrate at ~1.98 min.   
Similarly to LipK and Mra14, there was no activity seen with the amino acids Gly 
or Ser, the primary hypothetical amino acid donor.  However, a new peak was 
seen with the partially purified Orf25 when using L-Thr as previously observed 
with the other enzymes.  HPLC analysis revealed the enzymatic product eluted at 
~1.28 min (Fig.  3.15A). 
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3.2.4.2 Substrates and enzymatic activity of CapH 
The next putative SHMT of interest from the capuramycin-like compound A-
503083 biosynthetic gene cluster, CapH, was tested for activity.  Again, 2.0 mM 
UA, 0.1 mM PLP, and 10.0 mM of a variety of amino acid donors in 50 mM 
potassium phosphate buffer (pH 7.5) containing 5 µM of CapH were tested for 
enzymatic activity.  Individual reactions were prepared and incubated at 30°C for 
2 hr, 6 hr, and 18 hr and terminated by spin column filtration.  The reactions were 
then analyzed by reverse-phase HPLC utilizing a linear acetonitrile gradient.  
Once again, the control reaction containing all substituents except enzyme 
showed elution of the UA substrate at ~1.98 min and the primary hypothetical 
amino acid donors Gly or Ser showed no activity in any of the reactions. In 
contrast, and similarly to Orf25, HPLC analysis again revealed enzymatic activity 
with the amino acid L-Thr with the enzymatic product eluting at ~1.28 min (Fig. 
3.15B), consisten with GlyU as the product. 
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Figure 3.15.  Verification of enzymatic activity of the putative SHMTs 
isolated from the biosynthetic gene cluster of capuramycin-related 
compounds.  Reactions were carried out in 50 mM potassium phosphate buffer 
(pH 7.5), 0.1mM PLP, 10 mM L-Thr or Gly, and 2.0 mM UA.   (A)  Enzymatic 
activity involving the putative 5 µM SHMT, Orf25, from A-102395 biosynthetic 
gene cluster.  No activity was seen with the amino acid donor Gly while product 
formation was observed at 1.28 min with L-Thr.  (B)  Enzymatic activity involving 
the putative 5 µM SHMT, CapH, from A-503083 biosynthetic gene cluster.  
Again, no activity was seen with the amino acid donor Gly while product 
formation was observed at 1.28 min with L-Thr.   
	  
	  
3.2.5  Comparison of enzymatic activity of putative SHMTs 
Due to the high similarity in amino acid sequence, as well as a key lysine residue 
located at ~235 aa found in each enzyme, the selection of preferred substrates 
by each enzyme indicates an identical catalytic function of the putative SHMTs 
A 
B 
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(Table 3.2).  Comparison of the putative SHMTs utilizing UA, and L-Thr as 
substrates and PLP as a co-factor indeed gave identical HPLC chromatographs 
(Fig. 3.16).  This is further evidence that the putative SHMTs are involved in the 
biosynthesis of the core unit of both the caprazamycin and capuramycin-related 
compounds GlyU and CarU respectively.  Importantly, the results in total have 
led us to functionally assign these enzymes as LP-dependent UA: L-Thr 
transaldolases. 
 
Table 3.2.   Transaldolase sequence comparison.  Comparison of the amino 
acid sequence of the individual putative SHMTs.  %Identical/%Similar. 
	   LipK	   CapH	   Mra14	   Orf25	  
LipK	   X	   45/47	   81/82	   45/47	  
CapH	   45/47	   X	   46/48	   79/80	  
Mra14	   81/82	   46/48	   X	   45/47	  
Orf25	   45/47	   79/80	   45/47	   X	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Figure 3.16.  Transaldolase activity utilizing L-Thr and UA as primary 
substrates.    Reactions were carried out in 50 mM potassium phosphate buffer 
(pH 7.5), 0.1mM PLP, 10 mM L-Thr or Gly, and 2.0 mM UA.   The control reaction 
reflects reaction conditions lacking any enzyme.  LipK, Mra14, Orf25, and CapH 
were individually tested by addition of 5 µM, run at 30°C, and terminated by spin 
column after 18 hours. The substrate UA elutes at ~1.89 min while the enzymatic 
product of each of the afore mentioned enzymes elutes at ~1.29 min.  No activity 
was seen utilizing any other amino acid donor. 
 
3.3. Isotopic feeding experiments for the capuramycin-like compound A-
503083 
The results suggest GlyU is an intermediate in the biosynthesis of the uridine-5ʹ′-
carboxamide (CarU) core in the capuramycin-related compound biosynthesis.   In 
order to provide additional evidence for the shared biosynthetic mechanism in 
capuramycin and carazamycin-related compounds, isotopic tracer experiments 
were executed employing the strain that produces A-503083. [1-13C]Gly or [2-
13C]Gly and L-[13C4, 15N]Thr were used with the expectation that the first two 
would serve as negative controls while the last would lead to enrichment 
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3.3.1 Isotopic feeding of  [1-13C]Gly or [2-13C]Gly to the A-503083 B strain 
The isotopically labeled Gly was fed into the producing strain of A-503083 B, the 
aminocaprolactam-containing and major congener of the A-503083 compounds 
(Fig. 3.17A).  There was no significant enrichment observed for A-503083 B 
except for a 6% enrichment of the 3ʹ′-O-methyl group when fed the [2-13C]Gly into 
the producing strain	  (Fig. 3.17B-D).  This result is consistent with previous Gly 
tracer studies for other Streptomyces O-methylated metabolites (57).  
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Figure 3.17.  Isotopic tracer experiments using 13C-Gly. (A) Structure of A-
503083 B, the 6'''-desmethyl derivative of A-503083 A. (B) 13C-NMR spectrum of 
A-503083 B obtained without feeding (natural abundance 13C). (C) 13C-NMR 
spectrum of A-503083 B	  obtained with [1-13C]Gly feeding. (D) 13C NMR spectrum 
of A-503083 B obtained with [2-13C]Gly feeding. 
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3.3.2  Isotopic feeding of L-[13C4, 15N]Thr into the strain producing A-503083 
F
The isotopically labeled compound L-[13C4, 15N]Thr was fed into the producing 
strain of A-503083 F, the deaminocaprolactam derivative of A-503083 B and a 
minor congener produced by the strain (Fig. 3.18A).  In contrast to the [1-13C]Gly 
and [2-13C]Gly experiment, there was a 15% enrichment at the C-6ʹ′ position (Fig. 
3.18B-D).   Incorporation at this position is consistent with the direct incorporation 
of L-Thr by means of a transaldolase mechanism.  We also observed a C-6ʹ′ 
doublet within the 13C spectrum (JCN = 18 Hz) indicative of a preserved C-N bond 
from L-Thr during biosynthesis of CarU (Fig. 3.18E).  
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Figure 3.18.  Isotopic tracer experiments using L-[13C4,15N]Thr. (A) Structure 
of A-503083 F, the deaminocaprolactam derivative of A-503083 A. (B) HPLC 
analysis of the purified A-503083 F obtained without feeding (natural abundance 
13C) and with L-[13C4,15N]Thr feeding. (C) Mass spectra for the peak eluting at t = 
5.2 min, comparing A-503083 F isolated without feeding (blackbars) and with L-
[13C4,15N]Thr feeding (redbars). (D) 13C-NMR spectrum of A-503083 F obtained 
without feeding (natural abundance 13C). (E) 13C-NMR spectrum of A-503083 F 
obtained withL-[13C4,15N]Thr feeding. 
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3.4. Biochemical analysis of the model enzyme LipK 
 
3.4.1 Co-factor determination of  the model enzyme of LipK 
A useful characteristic of PLP-dependent enzymes is the unique UV/VIS 
spectrum associated with the binding of the co-factor and formation of catalytic 
intermediates.  During the reaction coordinate formation of the internal aldimine, 
or holo-enzyme, followed by amino acid binding to form the external aldimine 
exhibits a UV maximum near 425 nm.   Both SHMTs and LTAs elicit a UV 
maximum near 425 nm upon binding of the B6 derived cofactor PLP and 
formation of the internal aldimine (Fig.3.19A). (4, 43). Contrastingly, LTA forms a 
quininoid intermediate upon Cα abstraction of Gly shifting the UVmax to 492 nm, 
while SHMTs retaining the same profile until THF binding to form a ternary 
complex, thus shifting the maximum to 500 nm (Fig. 3.19A).    
 
Analysis of EcGlyA, EcLTA, and LipK revealed a UV/Vis spectra consistent with 
PLP bound to the protein as purified.  The model enzyme LipK originating from 
both S. lividans TK64 and S. albus displayed a UVmax at 416 nm (Fig. 3.19B and 
Fig. 3.19F) which was absent in the LipK(K235A) mutant (Fig. 3.19F).  The 
EcLTA displayed a maximum absorbance at 421 nm (Fig. 3.19C), while the 
EcGlyA at 425 nm (Fig. 3.19D).  As expected, upon addition of Gly, the EcLTA 
shifted the UVmax to 492 nm (Fig. 3.19C) and the EcGlyA UVmax shifted to 500 
nm upon the addition of both THF and Gly (Fig. 3.19D).  These shifts in UVmax 
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are both consistent with the formation of a quininoid intermediate.  In contrast, 
addition of either Gly, THF, or both did not alter the UVmax of LipK (Fig. 3.19E).  
This data suggests that LipK has unique catalytic properties differing from those 
of EcGlyA and EcLTA. 
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Figure 3.19.  UV/Vis spectra for intermediates and the potential 
intermediates of the PLP-dependent enzymes under analysis. (A) Formation 
of the internal aldimine with the binding of the apo-enzymes to PLP generating 
the holo-enzyme (I) followed external aldimine formation by Gly binding (II). A 
quininoid intermediate is observed by UV/VIS spectroscopy due to deprotonation 
at the α-carbon within the active site of LTA. (III). In contrast, SHMT binding of the 
substrate analogues of N5,N10-methylene tetrahydrofolate (THF) such as THF to 
form a ternary complex that undergoes deprotonation at the α-carbon of Gly to 
yield a quininoid intermediate (IV). However, no UV/Vis spectral changes were 
identified with LipK therefore precluding the assignment of any intermediates that 
are depicted. (B) UV/Vis spectrum of LipK isolated from Streptomyces albus. (C) 
UV/Vis spectrum of EcLTA as isolated (holo-EcLTA), following the addition of Gly 
(+Gly), and following addition of Gly with 2 (+Gly and 2). The reduction in the 
peak at 492 nm following the addition of 2 suggests either a reaction is occurring 
or 2 binding is promoting re-formation of aldimine II, in both cases preventing the 
accumulation of a quininoid intermediate. As subsequently determined, the 
inability to observe any product by HPLC is consistent with the latter. (D) UV/Vis 
spectrum of EcGlyA as isolated (holo-EcGlyA), following the addition of Gly 
(+Gly), and following addition of Gly with THF (+Gly and THF). (E) UV/Vis 
spectrum of LipK as isolated (holo-LipK), following the addition of Gly (+Gly), and 
following addition of Gly with 2 or THF (+Gly and 2 or THF).  (F) The UV/Vis 
spectra of recombinant LipK and point mutant isolated from S. lividans TK64. AU, 
absorbance units. 
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3.4.2  Specificity and biochemical properties of LipK
In order to develop assays capable of measuring LipK activity, optimal reaction 
conditions were determined.  By identifying optimal pH, buffer conditions, and 
potential substrates, we were able to determine conditions suitable for kinetic 
analysis.  Kinetic analysis utilized the formation of a secondary product during 
the LipK reaction, acetaldehyde.   
3.4.2.1 Optimization of LipK enzymatic activity 
 3.4.2.1a  L-Thr specificity for LipK activity 
We first explored LipK activity with different α-amino acids and detection by 
HPLC.  The only activity seen was that utilizing L-Thr as the amino acid donor.  
The lack of activity with proteinogenic α-amino acids, commercially available L-
Thr diasteromers, and Thr analogues (Fig. 3.20) indicates the high specificity for 
L-Thr.   
 3.4.2.1b Optimal pH and buffer for LipK activity  
A variety of buffers capable of maintaining various pH profiles was tested to 
determine the optimal pH for activity.  Succinate, citrate, phosphate, Tes, Hepes, 
and Tris buffers were prepared in pH profiles ranging from 3-10 and tested.  The 
pH profile for LipK resembles a bell shaped curve under initial velocity conditions 
and maintained an optimal pH activity at 7.5 with the optimal buffer being Tes 
(Fig. 3.21A).   
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 3.4.2.1c  Optimal salt concentration for LipK activity 
The monovalent cations K+ and Na+ have shown activation of enzymatic activity 
by enhancing the affinity of the enzyme for the substrate (58).  Therefore, 
monovalent cation concentration was tested between 0.001-10000 mM.  
Monovalent ions slightly changed the activity up to 100mM and then began to 
decrease activity (Fig. 3.21B). 
 
	  
Figure 3.20.  HPLC analysis to probe the substrate specificity of LipK. The 
reactions were carried out in 50 mM HEPES (pH 7.5), 2 mM 2, 5 mM indicated 
co-substrate (all α-amino acids), 0.1 mM PLP, and 2 µM LipK at 30 °C for 1 h 
prior to termination. Product formation was monitored using the Agilent HPLC 
system with an Eclipse XDB-C18 column. (o) 2 (•) 1. A260, absorbance at 260 nm. 
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Figure 3.21.  Activity optimization for LipK.  (A) pH profile of LipK. The activity 
was assessed in reactions containing 50 mM buffer,2 mM uridine-5'-aldehyde, 5 
mM L-Thr,0.1 mM PLP, and 2 µM LipK at 30 °C under initial velocity conditions. 
Product formation was assessed by HPLC. (B)Activity of LipK with monovalent 
salts using 50 mM TES (pH 7.5)and the conditions indicated in A. 
 
3.4.2.2 Assay development for enzymatic activity   
After optimizing conditions for enzymatic activity for LipK, we tested for L-Thr 
dependent retro-aldol activity in which we utilized the formation of acetaldehyde 
during the reaction to develop an assay amicable to kinetic analysis.  
Saccharomyces cerevisiae aldehyde dehydrogenase (ADH, EC 1.2.1.3) 
efficiently utilizes acetaldehyde as a substrate for oxidation by reduction of β-
NAD+ (Fig. 3.22).  To verify the formation of acetaldehyde, we also compared 
results to that of EcLTA and EcGlyA. 
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Figure 3.22.  The LipK-catalyzed reaction and coupling with 
aldehyde dehydrogenase (ADH). 
 
 
First, we ensured conditions for ADH activity did not interfere with the activity of 
the LipK, EcLTA, and EcGlyA (Fig. 3.23).  This assay revealed that a retro-aldol 
reaction was catalyzed solely with L-Thr and LipK, EcLTA, and EcGlyA yielding 
activities of (1.3 ± 0.2) x 10-2, 1.2 ± 0.2, and (5.7 ± 0.4) x 10-4 µmol/min/mg, 
respectively (Fig. 3.24 and 3.25A).   
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Figure 3.23.  Assay Development for LipK. (A) HPLC analysis of the LipK 
reaction starting with 2 after 2 h reactions with omission of L-Thr (I), all necessary 
reaction components (II), reaction components plus 1 mM β-NAD+ (III), reaction 
components plus 1 mM β-NAD+ and 1 mM DTT (IV), reaction components plus 1 
mM β-NAD+, 1 mM DTT, and 100 mM KCl (V). The results demonstrate that LipK 
activity is not affected by β-NAD+, DTT, or KCl at these concentrations. Reactions 
were monitored using the Agilent HPLC system with an Eclipse XDB-C18 
column. β-NAD+, β−nicotinamide adenine dinucleotide, oxidized form; oxDTT, 
oxidized dithiothreitol; A260, absorbance at 260 nm. (B) UV/Vis spectroscopic 
analysis of the LipK and aldehyde dehydrogenase (ADH)-coupled reaction 
monitoring the reduction of β-NAD+. ADH did not oxidize 2, pyridoxal-5'-
phosphate (PLP), nor TES buffer, and oxidation activity of acetaldehyde was not 
affected by the necessary components for LipK activity. 1X corresponds to 0.004 
U of ADH. A340, absorbance at 340 nm. 
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Figure 3.24.  L-Thr aldolase activity. Reactions were conducted in 50 mM TES 
(pH 7.5), 100 mM KCl, 1 mM DTT, 0.1 mM PLP, 10 mM L-Thr, 2 mM β-NAD+ at 
30 °C (A) LipK at 33 µg (▲), 62.5 µg (■) and 96 µg (●) yielding a specific activity 
of (1.3 ± 0.2) x 10-2 µmol/min/mg. (B) EcLTA at 0.12 µg (▲), 0.5 µg (■) and 1.7 
µg (●) yielding a specific activity of 1.2 ± 0.2 µmol/min/mg. (C) EcGlyA at 300 µg 
(▲), 750 µg (■) and 1180 µg (●) yielding a specific activity of (5.7 ± 0.4) x 10-4 
µmol/min/mg. A340, absorbance at 340 nm. 
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Although the detection of acetaldehyde with LipK was surprising, the rate of 
retro-aldol activity catalyzed by LipK was significantly increased upon an 
equimolar addition of UA (Fig. 3.25A), which suggests that the normal catalytic 
cycle involves an initial binding of L-Thr and formation of a ternary complex.  The 
single-substrate kinetics experiments utilizing LipK displayed the typical 
Michaelis-Menten kinetics in regards to UA and yielded constants of Km = 29.2 ± 
9.5 mM and kcat = 40 ± 4 min-1 (Fig. 3.25B).  However, while the high Km  for UA 
precluded an accurate single-substrate kinetic analysis with respect to varied L-
Thr, the bisubstrate kinetic analysis was consistent with LipK utilizing a 
sequential mechanism more characteristic of bona fide SHMTs despite the 
production of acetaldehyde in the absence of UA (Fig. 3.25C) (54). 
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Figure 3.25.  Kinetic analysis of LipK. (A) UV/Vis spectroscopic analysis of the 
L-Thr retro-aldol-type reaction catalyzed by LipK in the absence or presence of 
10 mM 2. Each line represents an independent reaction with 2 added at the 
indicated time. A340, absorbance at 340 nm. (B) Single-substrate kinetic analysis 
with 30 mM L-Thr and variable 2. (C) Bisubstrate kinetic analysis using 1 mM (■), 
3 mM (▲), and 60 mM (●) 2.    
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3.5. Exploration of EcGlyA and EcLTA as L-threonine Transaldolases 
The initial bioinformatics analysis of the four enzymes studied in this dissertation 
gave the highest similarity to PLP dependent serine hydroxymethyltransferases.  
However, the actual function is revealed to be an L-Thr transaldolase.  Knowing 
that the putative SHMT LipK is actually a transaldolase, we decided to test both 
EcGlyA and EcLTA, well characterized SHMT and LTA respectively, for 
transaldolase activity.   
 
3.5.1  Enzymatic activity with L-Thr and UA as primary substrates 
The initial experiment combined PLP, TES buffer, Gly, and UA with either 
EcGlyA or EcLTA and subjected to HPLC analysis.  (43, 59)  Initial screening 
revealed no activity with Gly, however a low amount of activity with L-Thr was 
observed (Fig. 3.26).  The new peaks had identical retention time and UV 
spectrum to the LipK product, GlyU.  The stereochemistry of this reaction product 
is under investigation. 
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Figure 3.26.  Detection of potential (trans)aldolase activity of EcGlyA and 
EcLTA. HPLC analysis of 18 h reactions containing 5 µM enzyme and 2 with 
control (no enzyme, I), EcLTA with Gly (II), EcLTA with L-Thr (III), EcGlyA with 
Gly (IV), EcGlyA with L-Thr (V), and LipK with L-Thr (VI). (o) 2, (●) new peak co-
eluting with 1. A260, absorbance at 260 nm. 
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3.5.2  Enzymatic activity with L-Thr and 2-pyridine-carboxaldehyde as 
primary substrates
Due to the enzymatic activity seen with UA and  L-Thr, with either EcGlyA and 
EcLTA in comparison to LipK, the potential L-Threonine transaldolase activity of 
EcGlyA and EcLTA was further explored with the alternative aldehyde 
substrates. The commercially available substrates 2-pyridine-carboxaldehyde 
and L-Thr were tested for enzymatic activity with EcGlyA and EcLTA, using 
reverse-phase HPLC and MS for detection and analysis.  
 
3.5.2.1  HPLC analysis of enzymatic reactions involving EcGlyA (EcSHMT), 
EcLTA, and 2-pyridine-carboxaldehyde
Reactions incorporating 0.1 mM PLP, 10.0 mM L-Thr, 2.0 mM 2-pyridine-
carboxaldehyde, and 5 µΜ enzyme were incubated for 18 h.  The reactions were 
analyzed by reverse-phase HPLC chromatography following a linear acetonitrile 
gradient.  The control reaction lacking any enzyme shows elution of the 2-
pyridine-carboxaldehyde at ~1.93 min.  Reactions containing 5 µM of the 
specified enzyme indicate enzymatic activity by the formation of a new peak at 
~1.53 min.  Both EcGlyA and EcLTA show identical chromatographs to that of 
the reaction containing LipK (Fig. 3.27A).   
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3.5.2.2  MS analysis of enzymatic reactions involving EcGlyA, EcLTA, and 
2-pyridine-carboxaldehyde. 
The new peak was collected and subject to HPLC analysis for purity and MS 
analysis for preliminary identification of the product. The EcGlyA product 
appeared pure while the EcLTA product showed only minor contamination in the 
chromatograph (Fig. 3.27D and Fig. 3.27E).  Interestingly, both the EcGlyA 
product and the EcLTA product showed a (M – H)+ ion at m/z = 183.2 (Fig. 3.27B 
and Fig. 3.27C), consistent with that of 4 (expect m/z = 182), the L-Thr 
transaldolase product of 2-pyridine-carboxaldehyde and L-Thr (Fig. 3.27F).  The 
structure and stereochemical assignment of the product is under investigation. 
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Figure 3.27.  HPLC and MS analysis of EcSHMT and EcLTA  transaldolase 
activity utilizing L-Thr and 2-pyridine-carboxaldehyde as primary 
substrates.  (A)  HPLC analysis of 18 h reactions with no enzyme in the control, 
5 µM EcLTA, 5µM EcGlyA, and 5 µM LipK. Abs(254), absorbance at 254 nm.  
(B)  Mass spectrum for the peak eluting at t = 1.53 min from the enzymatic 
product of 2-pyridine-carboxaldehyde, L-Thr, PLP, and EcGlyA.  The product 
yields an ion of mass (M – H)+ consistent with the molecular formula of 4.  (C) 
Mass spectrum for the peak eluting at t = 1.53 min from the enzymatic product of 
2-pyridine-carboxaldehyde, L-Thr, PLP, and EcLTA.  The product yields an ion of 
mass (M – H)+ consistent with the molecular formula of 4.  (D)  HPLC trace of the 
EcGlyA enzymatically prepared product following purification using reverse-
phase chromatography.  (E)  HPLC trace of the EcLTA enzymatically prepared 
product following purification using reverse-phase chromatography.  (F)  L-
threonine transaldolase activity incorporating L-Thr onto 2–pyridine-
carboxaldehyde.  
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Chapter Four 
 
Summary 
The caprazamycin and capuramycin-related compounds A-90289, 
muraminomicin, A-503083, and A-102395 are potent MraY inhibitor compounds 
with great potential for antibacterial use within the clinical setting.  Their complex 
and novel structures help to delay the onset of resistance while their non-
mammalian homolog targets are specific for gram-positive and gram-negative 
peptidoglycan cell wall formation.  By investigating the biosynthetic pathway 
utilized in the formation of these compounds, we were able to identify enzymatic 
homologs suggesting similar biosynthetic pathways in these two families.  
Characterization of these shared enzymatic homologs revealed novel and 
interesting chemistry.  
 
Herein we have described the novel chemistry utilized by the putative SHMTs 
within the caprazamycin and capuramycin-related compounds that catalyze C-C 
bond formation that is necessary in assembling the high carbon furanoside. The 
MraY translocase I inhibitor compounds  A-90289 isolated from Streptomyces sp. 
SANK 60405, muraminomicin isolated from Streptosporangium amethystogenes 
SANK 60709k, A-503083 isolated from Streptomyces sp. SANK 62799, and A-
102395 from Amycolatopsis sp. SANK 60206 all share this putative SHMT within 
the biosynthetic gene cluster.  Previous research in our group has already shown 
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the necessity of the putative SHMTs in the formation of the final compound due 
to the abolishment of product when the SHMT-like gene is deleted from the 
biosynthetic gene cluster.  Therefore, we turned to heterologous expression of 
the putative SHMTs from each of the above-mentioned compounds for in vitro 
analysis of enzymatic activity and characterization of the enzymatic product.  
Interestingly we were only able to get soluble protein from Streptomyces host.  
Perhaps more interesting was the discovery of the true activity of these SHMT 
homologues as L-Thr UA transaldolases.  This is in contrast to our first 
hypothesis that Gly or Ser was used as a glycyl unit donor. 
 
After identification of (5S, 6S)-GlyU as the enzymatic product, we tested our next 
hypothesis that the putative SHMTs could serve as an intermediate in the 
formation of CarU, the core structure of the capuramycin-related compounds.  As 
expected, based on sequence similarity, Orf25 and CapH had identical activity to 
LipK and Mra14.  Furthermore, isotopically labeled precursors enabled us to 
identify L-Thr incorporation into the final compound  A-503083 and helped us to 
verify the activity and necessity of the putative SHMTs in formation of the CarU 
structure.  This result suggest more interesting chemistry is yet to be discovered 
during the conversion of GlyU to CarU during capuramycin biosynthesis. 
 
Finally, identification of the enzymatic activity of the putative SHMTs and the role 
they play in the biosynthesis of caprazamycin and capuramycin-related 
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compounds led us to inquire into a potential alternative activity of the canonical 
SHMT and LTA, GlyA and EcLTA respectively. Analysis of the results from the 
enzymatic assays using the putative SHMT LipK, as well as EcGlyA and EcLTA, 
revealed identical HPLC traces as well as the formation of acetaldehyde, the 
secondary product.  Preliminary results indicate that indeed both the EcGlyA and 
the EcLTA do act in a mechanistic method mimicking that of the transaldolase 
isolated from the caprazamycin and capuramycin-related compounds.  Overall, 
the heterologous expression, characterization, and in vivo analysis of the putative 
SHMTs studied in this dissertation offers insight into novel chemistry utilized by 
organisms to form novel, complex antibacterial compounds. 
 
  
Copyright © Sandra Hummel Barnard 2013	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Chapter Five 
Final Thoughts 
The continual search for methods enabling the formation of β-hydroxy-α-amino 
acids continues throughout the scientific community.  The requirement of β-
hydroxy-α-amino acids in formation of biologically active antibiotics make them 
ideal scaffolds to build novel antibacterial compounds, however the ability to 
synthesize enantiomerically pure products still remains challenging (60-63).   
 
This dissertation has revealed the LipK family of L-threonine:uridine-5ʹ′-aldehyde 
transaldolases as putative SHMTs that catalyze an L-Thr-dependent β-
substitution reaction by means of a sequential Cα-Cβ bond breaking and re-
formation (Fig. 4.1) to form the nonproteinogenic β-hydroxy-α-amino acid (5ʹ′S, 
6ʹ′S)-GlyU intermediate.   Differing in its preference for L-Thr as opposed to L-allo-
Thr preferred by canonical LTAEs (4), LipK displays activity similar to that of 4-
fluorothreonine transaldolase (FTase).  Despite sharing only 25% sequence 
identity within the SHMT-like domain (Fig. 4.2), both LipK and FTase catalyze an 
L-Thr-dependent β-substitution reaction by means of a Cα-Cβ bond breaking and 
creation (64, 65).  With the Lys residue identified as key in the formation of an 
external aldimine, and the C-C bond extension capability, LipK paves the way for 
inquiry into the more canonical enzymes EcGlyA and EcLTA, also utilizing 
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external aldimine formation and C-C bond extension, which we have tagged as 
having potential L-Thr transaldolase activity. 
 
Providing another distinct mechanism for C-C bond formation for sugars, LipK 
differs from the more traditional aldolase and transketolase group of enzymes 
which employ a carbonyl-group-containing substrate as the donor (66).  Instead, 
LipK uses an amino acid as the donor and yields a β-sugar substituted α-amino 
acid.  Not only could the ability of these novel enzymes for C-C bond formation 
provide another means of preparing previously un-synthesizable sugars and 
unusual amino acids, but the amalgamating ability utilizing amino acids into 
nucleoside antibiotics may provide another means for identifying complex, novel 
antibacterial compounds.    
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Figure 4.1  Putative chemical mechanism of L-Thr:UA transaldolases. The 
enzyme in the holo-form (I) binds L-Thr to generate the external aldimine (II) and 
UA to form a ternary complex. An enzyme base deprotonates the β-hydroxyl to 
initiate the retro-aldol-type reaction, a step that is likely rate limiting considering 
no additional UV-active intermediates such as species III are detected throughout 
the course of the reaction. The formed acetaldehyde subsequently diffuses from 
the active site allowing UA to position in the same relative orientation. Attack of 
III on the si face in the aldol-type reaction with UA generates intermediate IV 
prior to release of the two products and regeneration of the holo-enzyme I. In the 
absence of UA, a retro-aldol reaction can occur to putatively generate 
intermediate III, which was not detected by UV/Vis spectroscopy. 
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Figure 4.2.  Enzymes catalyzing an L-Thr-dependent β-substitution. (A) 
Reaction catalyzed by 4-fluorothreonine transaldolase (FTase). The activity was 
initially discovered based on isolation of the native enzyme from the 4-
fluorothreonine producing-strain Streptomyces cattleya. (B) Sequence alignment 
of FTase and LipK. FTase, the sequence of which was identified using reverse 
genetics, consists of two putative domains: an N-terminal SHMT-like domain and 
a C-terminal phosphate-binding domain of bacterial sugar epimerases and 
aldolases. One such epimerase homologue, AraD, catalyzes a reversible retro-
aldol reaction with ribulose-1-phosphate. Due to limiting expression levels, 
recombinant FTase that was partially purified from Streptomyces lividans was 
used solely to reconstitute the biosynthetic pathway of 4-fluorothreonine, thus the 
exact function of each domain remains undefined. LipK has a relatively low 
sequence identity of 25% (36% similarity) to the N-terminal domain of FTase, but 
the results with LipK suggest the transaldolase activity is likely harbored within 
this domain. ▼, conserved Lys required for formation of the internal aldimine with 
pyridoxal-5'-phosphate. 
 
 
A 
▼	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